Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Burstein, Harold
Item TypeName
Academic Article American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Academic Article Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Academic Article The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Academic Article Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
Academic Article Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
Academic Article Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age.
Academic Article Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Academic Article Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Academic Article Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.
Academic Article Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer.
Academic Article Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Academic Article Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
Academic Article CMF revisited in the 21st century.
Academic Article Adjuvant chemotherapy in older women with early-stage breast cancer.
Academic Article Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.
Academic Article Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping.
Academic Article American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
Academic Article Invasive breast cancer.
Academic Article Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
Academic Article Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
Academic Article Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer.
Academic Article American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
Academic Article Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA.
Academic Article Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer.
Academic Article American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Academic Article NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Academic Article Adjuvant hormonal therapy for early-stage breast cancer.
Academic Article Cognitive side-effects of adjuvant treatments.
Academic Article Simplifying guidelines: we only need one adjuvant chemotherapy regimen for breast cancer.
Concept Chemotherapy, Adjuvant
Academic Article Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.
Academic Article Patients with triple negative breast cancer: is there an optimal adjuvant treatment?
Academic Article Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.
Academic Article Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Academic Article Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
Academic Article Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.
Academic Article Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Academic Article Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).
Academic Article Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
Academic Article Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Academic Article Adjuvant ovarian suppression in premenopausal breast cancer.
Academic Article Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
Academic Article Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Academic Article With better adjuvant therapy, does breast cancer stage still matter?
Academic Article Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Academic Article Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Academic Article Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
Academic Article Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary.
Academic Article Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
Academic Article Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.
Academic Article Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
Academic Article Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer.
Academic Article Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making.
Academic Article Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
Academic Article Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Academic Article Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Academic Article Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer.
Academic Article Duration of adjuvant trastuzumab: might less be more?
Academic Article Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Academic Article Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Academic Article Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Academic Article Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Academic Article A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Academic Article Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
Academic Article Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit.
Academic Article Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Academic Article Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Academic Article Multidisciplinary considerations in the treatment of triple-negative breast cancer.
Academic Article Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations.
Academic Article Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Academic Article Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
Search Criteria
  • Chemotherapy Adjuvant
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.